Physician profile
Lauren Gray
NPI 1912656414
$2,096.30
in general payments reported to CMS, 2019-2025
22 companies · $863 in 2025
The $863 reported for 2025 was more than what 77% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $291 · 2024: $942 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,089 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,088.78 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $483.13 | 2023-2025 | |
| Supernus Pharmaceuticals, INC. | $152.85 | 2024-2025 | Qelbree |
| Corium, LLC | $145.30 | 2023-2025 | Azstarys |
| Mdd US Operations, LLC | $129.88 | 2025 | Qelbree |
| Alkermes, INC. | $122.03 | 2023-2025 | Aristada, Lybalvi |
| Axsome Therapeutics, INC. | $114.77 | 2023-2025 | Auvelity |
| Lundbeck LLC | $105.58 | 2023-2024 | Rexulti |
| Biogen, INC. | $98.38 | 2024 | Zurzuvae |
| Teva Pharmaceuticals USA, INC. | $96.89 | 2023-2025 | Uzedy, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $95.75 | 2023-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $84.67 | 2024-2025 | Spravato, Invega Sustenna |
| Vanda Pharmaceuticals INC. | $80.33 | 2025 | Fanapt |
| Otsuka America Pharmaceutical, INC. | $71.87 | 2024-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $54.94 | 2025 | |
| Almatica Pharma LLC | $46.80 | 2023-2024 | Loreev Xr |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $46.20 | 2025 | Cobenfy |
| Idorsia Pharmaceuticals US INC | $37.12 | 2024-2025 | Quviviq, Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $35.50 | 2023-2025 | Trintellix |
| Itamar Medical INC | $34.14 | 2024-2025 | Watchpatone |
| Tris Pharma INC | $28.91 | 2024-2025 | |
| Neos Therapeutics, LP | $17.69 | 2024 | Adzenys Xr-Odt |
| Collegium Pharmaceutical, INC. | $13.57 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.